Humacyte Inc
humacyte.comHumacyte Inc (NASDAQ: HUMA) is a regenerative medicine company that develops and manufactures acellular tissue-engineered vessels (ATEVs) for surgical implantation. Revenue is generated through direct product sales of Symvess, its FDA-approved ATEV, sold via the company's own sales force to hospitals and surgical facilities, with distribution outside the United States handled through a partnership with Fresenius Medical Care. Humacyte operates in the regenerative medicine and vascular graft market. The company manufactures ATEVs at an 83,000 square foot bioprocessing facility and holds a patent portfolio of 15 patent families covering scaffolds, product composition, and manufacturing methods. As of December 31, 2025, cash, cash equivalents, and restricted cash totaled $50.9 million, and the company reported a net loss of $40.8 million for FY2025. Humacyte carries debt under a Term Loan Facility of up to $77.5 million with Avenue Venture Opportunities Fund II, of which $40.0 million was funded on December 15, 2025, maturing December 1, 2029. The company does not pay a dividend and has funded operations primarily through equity offerings and debt financing.
Products & Services
Symvess: an acellular tissue-engineered vessel (ATEV) approved for vascular repair, manufactured at an 83,000 square foot bioprocessing facility in multiple diameters and lengths. Pipeline ATEV product candidates targeting additional indications including peripheral artery disease and AV access for hemodialysis.
Revenue Model
Transactional product sales of Symvess to hospitals and surgical facilities through a direct sales force in the United States; revenue is recognized upon confirmation that the product has been used in a surgical procedure, including under consignment arrangements. International distribution revenue flows through a distribution agreement with Fresenius Medical Care.
Customers & Markets
Hospitals and surgical facilities performing vascular repair procedures. End markets include trauma and vascular surgery, hemodialysis AV access, and peripheral artery disease treatment. Clinical trial data (FY2025 10-K) shows ATEV functional patency at Month 6 of 85.7-89.2% versus 51.9-54.5% for arteriovenous fistula (AVF) comparators.
Geographic Exposure
Primary commercial market is the United States. International distribution handled on a country-by-country basis through Fresenius Medical Care, which holds discretionary termination rights outside the U.S.
Financial Snapshot
Loading...
